drugset / Trial / NCT05571787

HMPL-523 Food Effect and Proton Pump Inhibitor Study

NCT05571787

Phase 1 Completed 26 enrolled Hutchmed
RandomizedCrossoverOpen-labelOther

Summary

A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Timeline

Start
2022-07-13
Primary completion
2022-09-22
Completion
2022-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 40 mg Oral
Subject Sovleplenib Small molecule 700 mg Oral

Indications